What Huayu Wuxi Pharmaceutical Co. does

Huayu Wuxi Pharmaceutical Co. (华裕（无锡）制药有限公司) is a privately held, wholly foreign-owned specialty pharmaceutical manufacturer founded in 1994 in Wuxi, China. The company produces psychotropic, digestive, and cardiovascular prescription drugs across three therapeutic areas: psychiatric/neurological (mirtazapine tablets branded Paidisheng/派迪生), cardiovascular (urapidil injection branded Yayouding/裕优定), and gastroenterology (aluminum phosphate gel branded Yuer/裕尔). Its technology base centers on GMP-compliant manufacturing with vertically integrated API and finished dosage form production — including large volume injections, small volume injections, freeze-dried powder injections, tablets, hard capsules, granules, gels, creams, and rinses — operated from a Wuxi headquarters and a Liyang production base established in 2016. The R&D portfolio includes 4 invention patents and 18 utility model patents, and the company holds provincial recognition as the Jiangsu Province Engineering Research Center for Psychiatric Neurological and Anti-infective Drug Formulations. Multiple products are listed on the national essential drug list, and mirtazapine tablet has passed generic consistency evaluation and won a national centralized procurement (集采) bid.

The company's business model is sales-led, with regional sales managers covering all Chinese provinces through a direct sales network targeting medical institutions and pharmacies, supplemented by national volume-based procurement channel access. Revenue is generated through one-time prescription product sales across three therapeutic categories, with pricing not publicly disclosed and contract terms governed by national procurement where applicable. Customers are end-use patient populations requiring treatment for depression, hypertension crisis/management, and digestive disorders, accessed via healthcare providers rather than direct B2B relationships. The company is positioned as a niche specialty pharma manufacturer with regulatory moats from GMP certification, essential drug list inclusion, and procurement bid wins, but limited disclosed financial scale and an undisclosed foreign parent investor constrain visibility into strategic optionality and capital structure.

Name

Huayu Wuxi Pharmaceutical Co.

Legal name

华裕（无锡）制药有限公司

Website

https://hua-yu.com.cn

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1–10 employees

Short description

Huayu Wuxi Pharmaceutical Co. is a privately held, wholly foreign-owned Chinese specialty pharmaceutical manufacturer founded in 1994, producing psychotropic, cardiovascular, and digestive system drugs for healthcare institutions and pharmacies nationwide via direct sales and national volume-based procurement.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing (Specialty Prescription Drugs)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Oral Solid Dose (OSD) Generics (HLAIABAD), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Psychiatric medications
• Cardiovascular drugs
• Digestive system drugs
• Active pharmaceutical ingredients

Headquarters

HQ city

Wuxi Shi

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: The company generates revenue through manufacturing and selling pharmaceutical products including specialty drugs for psychiatric disorders (mirtazapine), cardiovascular conditions (urapidil injection), and digestive system treatments (aluminum phosphate gel). Products are sold through a nationwide sales network with some products included in national centralized procurement (national volume-based procurement/集采) program.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Huayu (Wuxi) Pharmaceutical Co., Ltd. manufactures and sells specialty prescription pharmaceuticals including psychotropic drugs (mirtazapine tablets), cardiovascular drugs (urapidil injection), and digestive system drugs (aluminum phosphate gel). The company produces finished dosage forms and APIs through GMP-compliant facilities in Wuxi and Liyang, distributing nationwide via a regional sales network and China's national centralized drug procurement program.

Product overview

Huayu (Wuxi) Pharmaceutical Co. is a modern high-tech pharmaceutical enterprise specializing in psychiatric medications, digestive system drugs, and cardiovascular/cerebrovascular medications. The company operates with a Wuxi headquarters and a Liyang manufacturing base. Key products include: Yu'er (Aluminum Phosphate Gel) for digestive applications, Paidisheng (Mirtazapine Tablets) for depression treatment, and Yuyouding (Urapidil Injection) for hypertension management. The company produces over 30 products including large volume parenterals, small volume injections, sustained-release capsules, and active pharmaceutical ingredients (APIs). The product portfolio focuses on specialized therapeutic areas including psychiatric/neurological medications and cardiovascular drugs.

Differentiator

Problem solved

Functional benefit

Brands

• 裕尔: 磷酸铝凝胶品牌
• 裕优定
• 派迪生

Products and services

• Yu'er Aluminum Phosphate Gel (裕尔 磷酸铝凝胶) Aluminum phosphate gel product indicated for digestive system applications. Manufactured by Huayu (Wuxi) Pharmaceutical Co., Ltd. and marketed under the Yu'er (裕尔) brand as part of the company's gastroenterology product line.
• Paidisheng Mirtazapine Tablets (派迪生 米氮平片) Film-coated mirtazapine tablets indicated for the treatment of depression, available in 15mg and 30mg strengths. Marketed under the Paidisheng (派迪生) brand. Has passed national generic drug consistency evaluation and won a bid in the new round of national centralized drug procurement.
• Yuyouding Urapidil Injection (裕优定 乌拉地尔注射液) Urapidil injection at 5ml:25mg specification, indicated for treatment of hypertensive crisis, severe and very severe hypertension, refractory hypertension, and perioperative hypertension control. Marketed under the Yuyouding (裕优定) brand as part of the cardiovascular specialty product line.
• Active Pharmaceutical Ingredients (APIs) - Aluminum Phosphate, Urapidil, Mirtazapine Bulk active pharmaceutical ingredients including aluminum phosphate (annual capacity 2,000kg), urapidil (15kg), and mirtazapine (18kg), manufactured at the Liyang production base for use in pharmaceutical formulation.
• Pramipexole Hydrochloride (new production project) New annual 2kg pramipexole hydrochloride production project approved by Wuxi Binhu District Economic and Trade Bureau. Indications relate to Parkinson's disease and restless legs syndrome treatment.

Quantifiable outcome

• 派迪生(米氮平片)已进入国家集采目录
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered minor.

• Third-party Environmental Monitoring OrganizationsminorImplementation/ SI/ Consulting Partner · 1 January 2023Commissioned third-party organizations to conduct self-monitoring work in accordance with pollution discharge permit self-monitoring plan requirements.
• Licensed Hazardous Waste Treatment Companies (资质单位)minorOthers · 1 January 2023Hazardous waste disposal contracted to qualified hazardous waste treatment companies with proper licenses.
• Changzhou Environmental Protection Bureau (常州市环境保护局)minorOthers · 1 March 2021Environmental impact assessment approval obtained for solid dosage form production line project (固体制剂生产线项目) in March 2021, approval document 常溧环省【2021】52号.
• Liyang Environmental Protection Bureau (溧阳市环境保护局)minorOthers · 1 September 2017Environmental impact assessment approval obtained for new pharmaceutical production line project (新建药品生产线项目) in September 2017. The project received approval document 溧环综发【2017】47号.
• Wuxi Environmental Science Research Institute (无锡市环境科学研究所)minorImplementation/ SI/ Consulting PartnerEnvironmental impact assessment agency engaged for pramipexole hydrochloride production project. Contact: 0510-85031860.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• CSPC Pharmaceutical Group: One of China's largest pharmaceutical manufacturers with broad therapeutic coverage including CNS, cardiovascular, and anti-infective drugs. Overlaps with Huayu's therapeutic areas and dosage form capabilities but at vastly larger scale, providing a benchmark for what a scaled-up version of Huayu's specialty model could become.
• Sino Biopharmaceutical: A leading Chinese pharmaceutical conglomerate with diversified therapeutic categories including cardiovascular, digestive, and CNS drugs. Comparable in product-line breadth to Huayu but operating at substantially larger scale with deeper R&D and a stronger national hospital sales network.
• Livzon Pharmaceutical Group: A mid-to-large Chinese pharmaceutical company with diversified specialty franchises in digestive, cardiovascular, and CNS therapeutics — closely matching Huayu's three specialty areas. Both companies combine finished dosage forms with API production and emphasize national hospital channels.
• Jiangsu Hengrui Medicine: China's largest innovative drug manufacturer with deep CNS, cardiovascular, and oncology franchises. Comparable in therapeutic areas but Hengrui operates at a much higher R&D and commercial scale, including its own injection manufacturing capabilities similar to Huayu's Liyang production base.
• China Resources Sanjiu Medical & Pharmaceutical: A leading state-backed Chinese pharmaceutical company with broad OTC and prescription drug coverage including cardiovascular and digestive categories. Comparable distribution through national hospital networks and essential drug list inclusion, but at significantly larger scale.
• Yangtze River Pharmaceutical Group: One of China's largest privately-held pharmaceutical manufacturers, with significant national hospital and essential drug list presence across multiple therapeutic areas. Comparable to Huayu in operating model (private, foreign-invested or domestic), dosage form diversity (tablets, injections), and dependence on Chinese public hospital channels.
• Humanwell Healthcare Group: A Chinese pharmaceutical group with diversified prescription drug franchises including CNS, reproductive health, and specialty areas. Provides a comparable mid-to-large specialty pharma model operating across multiple dosage forms and national hospital channels.

Direct peers

• Sichuan Kelun Pharmaceutical: A major Chinese manufacturer specializing in large volume parenterals (infusions), small volume injections, and APIs — directly comparable to Huayu's Liyang production base, which produces 50M+ bottles of large infusion and 10M ampoules of water injection annually. Both companies operate GMP-compliant facilities across multiple dosage forms for institutional hospital channels.
• Luye Pharma Group: A Chinese specialty pharmaceutical company with a strong focus on central nervous system (CNS) and oncology therapeutics. Luye's CNS franchise overlaps directly with Huayu's mirtazapine-based psychiatric franchise and provides a directly comparable business model in Chinese specialty psychotropic drug manufacturing.

Regional players

• Tianjin Tanabe Seiyaku: A Japanese-invested pharmaceutical manufacturer in China operating as a foreign-owned specialty drug producer. Provides a comparable ownership-structure and Chinese-market-focused operating model to Huayu's wholly foreign-owned enterprise status, even though therapeutic focus differs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Huayu Wuxi Pharmaceutical Co.